SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to rapidly escalating geopolitical tensions in the Middle East following reports of U.S.-Israeli strikes on Iran and subsequent retaliatory actions, with the community actively debating whether crude oil prices will surge higher on potential Strait of Hormuz disruptions or if the rally will prove temporary despite a significant military buildup in the region.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending due to U.S. intervention in Venezuela and escalating geopolitical tensions in the Middle East, particularly around the Strait of Hormuz, which is fueling a significant "war risk premium" in oil prices and leading the community to anticipate massive upside for energy stocks.

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound Ltd

MediWound is trending as investors eagerly anticipate a potential BARDA contract for its burn treatment NexoBrid, which recently showed strong efficacy in blast injuries, alongside promising advancements for its EscharEx chronic wound therapy. This momentum, including institutional interest and buyout speculation, is driving conversation despite polarized views on the stock's ability to break through current trading ranges.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating Middle East geopolitical tensions, including concerns over oil supply chokepoints like the Strait of Hormuz, are fueling community anticipation of surging crude prices and a potential short squeeze for this low-float energy stock.

Fan Tokens allow fans across multiple sports verticals to exercise their share of influence within their favourite teams/leagues/clubs. Through Socios.com, fans are empowered to participate in certain club decisions, for example, choosing a goal celebration song in a football stadium, choosing which fighters should go head to head in MMA, and more. Thanks to Fan Tokens, holders receive access to once-in-a-lifetime experiences such as player meet and greets, training day events &amp; much much more.  The growing list of partnerships launching their Fan Tokens on the Socios.com platform includes some of the biggest sporting organizations in the world such as FC Barcelona, Inter Milan, AC Milan, Manchester City, UFC, ROUSH Fenway Racing, Aston Martin, just to name a few.

Italian National Football Team Fan Token

The iShares U.S. Aerospace & Defense ETF (ITA) is trending amidst heightened global geopolitical tensions, including escalating conflicts in the Middle East and South Asia, prompting community discussion on potential impacts for defense spending and "war stocks." While some anticipate continued strength, others note recent profit-taking and market rotation out of the sector after a significant rally.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as intensifying geopolitical tensions in the Middle East, particularly regarding potential oil supply disruptions and the Strait of Hormuz, are driving crude prices higher. The community is actively discussing Chevron's strategic advantages, including expanded access to Venezuelan oil and new global exploration deals, positioning it for potential gains amid these market shifts.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending amid enthusiasm for positive Phase 3 clinical trial results for its HER2-positive breast cancer drug and encouraging lung cancer therapy data, fueling community discussions about its oncology pipeline and strategic pivot, even as some debate recent analyst upgrades against news of a partner offloading its stake.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

DIA is trending amidst escalating US-Iran geopolitical tensions, characterized by reports of military actions and leadership changes, coupled with market uncertainty following the Supreme Court's tariff ruling and subsequent threats of new tariffs from President Trump. The community is sharply divided between anticipating a potential market rally and fearing a significant downturn due to these events and broader economic concerns.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF ($MAGS) is a major talking point as its mega-cap tech holdings exhibit recent underperformance against the broader market, prompting community debate over a potential rotation into other sectors or the unwinding of an AI-driven valuation bubble.

Global X Funds - Global X Silver Miners ETF

The Global X Silver Miners ETF is actively discussed amid a tightening physical silver supply and surging industrial demand from AI and EVs, fueling a "silver squeeze" narrative. Despite current frustration over miners lagging the metal's price surge, the community widely anticipates a significant catch-up rally, viewing the sector as historically undervalued.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional...

D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Thursday...

Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One...

Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close.

Humacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a research note on Monday...

<ul class="summary-bullets"><li>The National Defense Authorization Act for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies to fix severe artery injuries in arms and legs.</li><li>This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.</li><li>Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.</li></ul>Humacyte Inc. (HUMA) on Monday announced that the recently adopted FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels.The company stated that the DOD funding is intended to support the evaluation and incorporation of biologic vascular repair technologies for warfighters with traumatic vascular injuries.Humacyte stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).<a href="https://stocktwits.com/symbol/HUMA">Humacyte shares</a> were up more than 30% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Does The NDAA Say?</h2>The National Defense Authorization Act (NDAA) for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies&nbsp;to fix severe artery injuries in arms and legs.This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.Autologous vein harvesting refers to the surgical removal of the patient’s own healthy vein, which is usually the great saphenous vein (GSV) in the leg. This is used as a graft, typically in coronary artery bypass grafting (CABG) or peripheral vascular surgery.“This historic, first-of-its-kind federal investment will help ensure our soldiers continue to have access to cutting-edge treatments and state-of-the-art care whenever and wherever they need it,” said Humacyte founder and CEO, Laura Niklason.<h2 class="st-heading-2">What Is Humacyte’s Symvess?</h2>Symvess is a human-derived biologic vessel&nbsp;used when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible.The company says Symvess is off-the-shelf and ready to use, with no immune response observed to date. It also states that Symvess has low susceptibility to infection.Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.<a href="https://stocktwits.com/symbol/HUMA">HUMA stock</a> is up 26% year-to-date, but down 71% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

Equity

Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.02, indicating a +2.24% shift from the previous trading day.

Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight ratings firms that are presently covering the stock, Marketbeat.com reports...

Humacyte (NASDAQ:HUMA) Given New $10.00 Price Target at Benchmark

Benchmark cut their target price on Humacyte from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday...

Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?

Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Humacyte Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.13	--	--	N/A
Q3 '25	-$0.15	-$0.11	27.17%	BEAT
Q2 '25	-$0.16	-$0.24	-48.35%	MISSED
Q1 '25	-$0.19	$0.28	246.83%	BEAT
Q4 '24	-$0.25	-$0.16	37.25%	BEAT

HUMA
Humacyte Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest HUMA News

HUMAHumacyte Inc